In the 26,808 identified at-risk patients, there were no postoperative myocardial infarctions. A post hoc power analysis was also performed to determine whether our results were powered to detect a difference in VTE rates. Chi-square analyses were used to identify differences in VTE rates between cohorts. From this cohort who received TXA intraoperatively, we identified patients with a history of CAD or coronary stents and determined the total myocardial infarction and venous thromboembolism (VTE) rates within a 90-day postoperative period. We performed a retrospective analysis at a single, tertiary academic medical center identifying consecutive total hip and knee arthroplasty cases over an 8-year period. The purpose of this study was to determine if TXA is safe to use in patients with a history of CAD or coronary stents. Although TXA has been shown to be highly effective in reducing operative blood loss, many surgeons believe that it places patients with coronary artery disease (CAD) or a history of coronary stents at an increased risk for myocardial infarction. Tranexamic acid (TXA) is increasingly used to minimize blood loss during total joint arthroplasty (TJA).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |